Ratings Gerresheimer AG

Equities

GXI

DE000A0LD6E6

Market Closed - Xetra Other stock markets 11:41:21 2024-04-26 am EDT			After market 12:45:09 pm
100.5 ^EUR	+1.31%		100.4	-0.05%

Apr. 22	GERRESHEIMER AG : Buy rating from Barclays	ZD
Apr. 22	GERRESHEIMER AG : Jefferies remains its Buy rating	ZD

Summary

The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The group shows a rather high level of debt in proportion to its EBITDA.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
Revenue estimates are regularly revised downwards for the current and coming years.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last few months, analysts have been revising downwards their earnings forecast.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
GERRESHEIMER AG	+5.62%	3.67B	B+
ABBOTT LABORATORIES	-2.92%	185B	C+
MEDTRONIC PLC	-3.80%	105B	C
BECTON, DICKINSON AND COMPANY	-5.48%	66.59B	A
DEXCOM, INC.	+11.22%	54.66B	B-
CENCORA, INC.	+16.74%	47.78B	B-
HOYA CORPORATION	+4.06%	41.26B	B+
WEST PHARMACEUTICAL SERVICES, INC.	+4.56%	26.95B	A-
METTLER-TOLEDO INTERNATIONAL, INC.	+1.64%	26.37B	B
TERUMO CORPORATION	+12.96%	24.8B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes